[Translation] Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics of XC2309 tablets in healthy subjects with single and multiple dose escalation and the impact of food on PK
评价健康受试者单次及多次服用XC2309 片后的安全性、耐受性、药代动力学特征;评价健康受试者空腹及餐后状态下服用XC2309 片的药代动力学特征,评价食物对药代动力学特征的影响;评价健康受试者单次及多次服用XC2309 片的药效学特征,为后期临床研究的剂量选择提供依据;探索鉴定健康受试者单次服用XC2309 片后人体内的主要代谢产物。
[Translation] To evaluate the safety, tolerability, and pharmacokinetic characteristics of XC2309 tablets in healthy subjects after single and multiple doses; to evaluate the pharmacokinetic characteristics of XC2309 tablets in healthy subjects in the fasting and postprandial states, and to evaluate The influence of food on pharmacokinetic characteristics; evaluate the pharmacodynamic characteristics of XC2309 tablets taken by healthy subjects in single and multiple doses to provide a basis for dose selection in later clinical studies; explore and identify the effects of XC2309 tablets taken by healthy subjects in single doses The main metabolite in the human body.